Date(s) - 09/16/2019
3:00 pm - 4:00 pm
This talk provides an overview of applications of a computational platform (Phenotypic Precision Medicine) to optimize combination therapy to markedly enhance efficacy and safety in the treatment of a variety of diseases of the liver. These include two independent approaches to the treatment liver cancer, a leading cause of cancer death worldwide and the only cancer whose mortality rate had increased over the last 10 years. I will also discuss optimization of immunosuppression after liver transplantation and fatty liver disease and non-alcoholic steatohepatitis.
Ali Zarrinpar, M.D., Ph.D., is associate professor in the Division of Transplantation and Hepatobiliary Surgery at the University of Florida, College of Medicine. Dr. Zarrinpar earned his medical degree from the University of California, San Francisco, where he also obtained a PhD in biochemistry. He completed a general surgery residency and a fellowship in multivisceral transplant and hepatobiliary surgery from the University of California, Los Angeles. He is a fellow of the American College of Surgeons and the American Society of Transplantation. He serves on the editorial board member of several journals and on multiple committees in American Society of Transplant Surgeons, Society for Lab Automation and Screening, among others. He has won a number of awards, including from SLAS, ACS, and ASTS. In addition to his clinical hepatobiliary and transplantation practice, Zarrinpar has an NIH funded research program in liver cancer, liver injury/disease, and transplant immunosuppression.